Harvard Medical School

Selected news for the hospital/health system - Harvard Medical School, collected since 10/2017. Recent stories appear in FiercePharma and Globe Newswire. This hospital/health system shares news with Massachusetts General Hospital, Public Health, State of Massachusetts, Infectious Disease, COVID-19 and hundreds of others.

Please provide a valid email address.
Shares Healthcare News With (link):
Healthcare Topics Public Health, Infectious Disease, COVID-19, Heart Disease, Medicare, National Institutes of Health, Mental Health, Clinical Research, Food and Drug Administration, Medical Education, Oncology, Coronavirus, Biotech, CDC, NIH, American Heart Association, Telehealth, American Medical Association, Medical Research, National Cancer Institute, Precision Medicine, Population Health, Gene Therapy, Medicaid, Patient Safety
Companies Merck, Pfizer, HealthDay
Health Systems Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Boston MA, Brigham and Women's Hospital, Boston Children's Hospital, Boston MA, Boston Children's Hospital, Beth Israel Deaconess Medical Center, Boston MA, Dana-Farber Cancer Institute, Boston MA, Cleveland Clinic, Mayo Clinic, Brigham and Women's Hospital, Boston MA
People Jemele Hill, Laura Hawks, David Grabowski, George Church
Locations State of Massachusetts, State of New York, Boston, Massachusetts, State of California, State of Washington, New York, New York, State of Texas

Selected Headlines

Date Headline (link) Source Relevant Snippet
7/6/2021 Innovation on hold during the pandemic? FDA says no with 29 approvals in first half of 2021 FiercePharma ... treatment Aduhelm. It was an approval so divisive that three members of the FDA’s advisory committee that reviewed the drug quit in protest. In his resignation letter to acting FDA commissioner Janet Woodcock, Harvard Medical School professor Aaron Kesselheim called the move a “debacle” and “probably the worst drug approval decision in recent U.S. history.” Within hours of its green light, Biogen ignited another firestorm when it ...
7/6/2021 Protagenic Therapeutics to Host Webinar with Dr. Maurizio Globe Newswire ... Department of Psychiatry at Massachusetts General Hospital, he is also Director of the Division of Clinical Research, Mass General Research Institute, Associate Dean for Clinical & Translational Research, and Slater Family Professor of Psychiatry at Harvard Medical School . In 2007, he founded and is now Executive Director of the Mass General Psychiatry Clinical Trials Network and Institute (“CTNI”), the first academic contract research organization (“CRO”) specialized in planning and ...
7/6/2021 Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET - Stocks News Feed stocksnewsfeed.com ... Department of Psychiatry at Massachusetts General Hospital, he is also Director of the Division of Clinical Research, Mass General Research Institute, Associate Dean for Clinical & Translational Research, and Slater Family Professor of Psychiatry at Harvard Medical School . In 2007, he founded and is now Executive Director of the Mass General Psychiatry Clinical Trials Network and Institute (“CTNI”), the first academic contract research organization (“CRO”) specialized in planning and ...
6/24/2021 Physician viewpoint: Monetizing EHRs with open data puts patients at risk Becker's Hospital Review ... create a firm that aggregates and sells deidentified data and gives more insight on medical conditions such as rare diseases and COVID-19.The article's authors are researchers from Boston Children's Hospital, Boston-based Harvard Medical School and Durham, N.C.-based Duke University Medical Center.Five things to know:HIPAA allows covered healthcare providers, payers and clearinghouses to use patient data freely once it has been deidentified. These policies enable ...
6/22/2021 Heart problems in vaccinated students trigger medical, legal scrutiny of campus COVID mandates legitgov.org ... professors suggest two more: the emergency use authorization (EUA) status of the COVID vaccines and widespread natural immunity. Younger adults and children have "extremely low" risk of mortality from COVID, epidemiologists Martin Kulldorff of Harvard Medical School and Jay Bhattacharya of Stanford Med wrote in an op-ed for The Hill Thursday ...
6/22/2021 Heart problems in vaccinated students trigger medical, legal scrutiny of campus COVID mandates legitgov.org ... professors suggest two more: the emergency use authorization (EUA) status of the COVID vaccines and widespread natural immunity. Younger adults and children have "extremely low" risk of mortality from COVID, epidemiologists Martin Kulldorff of Harvard Medical School and Jay Bhattacharya of Stanford Med wrote in an op-ed for The Hill Thursday ...
6/21/2021 Birthdays and COVID-19: New Analysis Reveals a Link focustechnica.com ... the pandemic.In counties with already high COVID-19 infection rates, birthday bashes may have fueled infection spread during the peak months of the pandemic, according to a new analysis led by researchers at Harvard Medical School and the RAND Corporation.The report, published today (June 21, 2021) in JAMA Internal Medicine , shows that in counties with high rates of COVID-19, households with recent birthdays were 30 percent more ...
6/21/2021 Birthdays and COVID-19: New Analysis Reveals a Link scitechdaily.com By Harvard Medical School June 21, 2021New analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic.In counties with already high COVID-19 infection rates, birthday bashes may have fueled infection spread during the peak months of the pandemic, according to a new analysis led by researchers at Harvard Medical School and the RAND Corporation.The report, published today (June 21, 2021) in ...
6/21/2021 I-Mab Appoints International Gastrointestinal Oncology Expert | IMAB Stock News stocktitan.net ... gastrointestinal cancers, particularly hepatobiliary cancers, and his influence in the international medical and research communities, would be greatly beneficial to the development of our novel programs."Dr. Zhu is a Professor of Medicine at Harvard Medical School , Director Emeritus of Liver Cancer Research at Massachusetts General Hospital as well as Chief Scientific Officer of Jiahui Health and Director of Jiahui International Cancer Center (JICC) in Shanghai . His clinical and research ...
6/21/2021 I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board PR Newswire ... particularly hepatobiliary cancers, and his influence in the international medical and research communities, would be greatly beneficial to the development of our novel programs."Â ÂDr. Zhu is a Professor of Medicine at Harvard Medical School , Director Emeritus of Liver Cancer Research at Massachusetts General Hospital as well as Chief Scientific Officer of Jiahui Health and Director of Jiahui International Cancer Center (JICC) in Shanghai . His clinical and research ...
6/21/2021 I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board intellasia.net ... gastrointestinal cancers, particularly hepatobiliary cancers, and his influence in the international medical and research communities, would be greatly beneficial to the development of our novel programs."Dr. Zhu is a Professor of Medicine at Harvard Medical School , Director Emeritus of Liver Cancer Research at Massachusetts General Hospital as well as Chief Scientific Officer of Jiahui Health and Director of Jiahui International Cancer Center (JICC) in Shanghai . His clinical and research ...
6/16/2021 Health Care Workers: Get the COVID-19 Vaccine Now infectioncontroltoday.com ... he can understand medical exemptions. But non-medical exemptions? Not so much. Sax is the clinical director of the infectious disease clinic at Brigham and Women’s Hospital and a professor of medicine at Harvard Medical School . When Houston Methodist Hospital made headlines last week by suspending for two weeks 178 employees who refused to get the COVID-19 vaccine, Sax immediately tweeted his backing of the move, adding that ...
6/13/2021 Is The U.S. Food and Drug Administration body Infallible? blogspot.com ... decisions." "This will undermine the care of these patients, public trust in the FDA, the pursuit of useful therapeutic innovation, and the affordability of the health care system."Dr. Aaron Kesselheim, professor of medicine, Harvard Medical School , resigning from the FDA’s Peripheral and Central Nervous System Advisory Committee Aduhelm by Biogen Source: BiogenThere is no cure for this dread disease of dementia that usually strikes the elderly, and ...
6/11/2021 Third member of FDA advisory panel resigns over Alzheimer's drug approval The Hill ... agency's controversial approval of an Alzheimer's drug this week.In a resignation letter sent to acting FDA Commissioner Janet Woodcock on Thursday and shared with The Hill, Aaron Kesselheim, a professor of medicine at Harvard Medical School , said the approval of Biogen's Alzehimer's drug "was probably the worst drug approval decision in recent U.S. history."FDA approved the drug , called Aduhelm, over the objections of its 11-member outside advisory ...
6/11/2021 Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug gleeconsultinggroup.com ... Food and Drug Administration advisory panel has resigned over the agency’s controversial decision to approve Biogen ‘s new Alzheimer’s drug, Aduhelm, CNBC has learned.Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School , said the agency’s decision on Biogen “was probably the worst drug approval decision in recent U.S. history,” according to his resignation letter obtained by CNBC.“At the last minute, the agency ...
6/11/2021 3 FDA Advisory Panel Members Resign Over Agency's Approval of Alzheimer's Drug From Biogen latinpost.com ... READ NEXT:Â U.S. to Buy 500 Million Pfizer COVID-19 Vaccines to Share Through COVAX AllianceFDA Advisory Panel Members Resigns Over the Approval of Alzheimer's Drug From Biogen Professor Aaron Kesselheim of Harvard Medical School , Dr. Joel Perlmutter of Washington University, and Dr. David Knopman of Mayo Clinic were the three members of the FDA's advisory committee who resigned this week."This might be the worst approval decision ...
6/11/2021 Third member of U.S. FDA advisory panel resigns over Alzheimer's drug approval wnflsports.com ... Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s Alzheimer’s disease treatment despite the committee’s recommendation against doing so.Aaron Kesselheim, a Professor of Medicine at Harvard Medical School who had served on the FDA’s advisory committee for nervous system drugs since 2015, told Reuters on Thursday he was stepping down from the panel.“My rationale was that the FDA needs ...
6/11/2021 Third member of U.S. FDA advisory panel resigns over Alzheimer's drug approval kfgo.com ... Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s Alzheimer’s disease treatment despite the committee’s recommendation against doing so.Aaron Kesselheim, a Professor of Medicine at Harvard Medical School who had served on the FDA’s advisory committee for nervous system drugs since 2015, told Reuters on Thursday he was stepping down from the panel.“My rationale was that the FDA needs ...
6/11/2021 Third member of U.S. FDA advisory panel resigns over Alzheimer's drug approval mymixfm.com ... Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s Alzheimer’s disease treatment despite the committee’s recommendation against doing so.Aaron Kesselheim, a Professor of Medicine at Harvard Medical School who had served on the FDA’s advisory committee for nervous system drugs since 2015, told Reuters on Thursday he was stepping down from the panel.“My rationale was that the FDA needs ...
6/11/2021 Third member of U.S. FDA advisory panel resigns over Alzheimer's drug approval go955.com ... Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s Alzheimer’s disease treatment despite the committee’s recommendation against doing so.Aaron Kesselheim, a Professor of Medicine at Harvard Medical School who had served on the FDA’s advisory committee for nervous system drugs since 2015, told Reuters on Thursday he was stepping down from the panel.“My rationale was that the FDA needs ...